编译:Ivy、Haozhen在深刻变革且日益艰难的美国医疗环境中,新药的研发与商业化正遭遇多重结构性阻力:监管持续收紧、临床试验成本高昂,而仿制药体系在压低价格的同时又造成质量不稳与供应脆弱,医疗支付端则长期存在定价扭曲与激励错配。在这样一套高度摩擦、效率受限的体系中,要推动真正意义上的创新变得愈发困难。正是在这种背景下,拥有百年历史的礼来仍然实现了跨周期的跃迁:从胰岛素时代迈入 GLP-1 时代...
Source Link编译:Ivy、Haozhen在深刻变革且日益艰难的美国医疗环境中,新药的研发与商业化正遭遇多重结构性阻力:监管持续收紧、临床试验成本高昂,而仿制药体系在压低价格的同时又造成质量不稳与供应脆弱,医疗支付端则长期存在定价扭曲与激励错配。在这样一套高度摩擦、效率受限的体系中,要推动真正意义上的创新变得愈发困难。正是在这种背景下,拥有百年历史的礼来仍然实现了跨周期的跃迁:从胰岛素时代迈入 GLP-1 时代...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.